301 related articles for article (PubMed ID: 30919077)
41. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
42. UNTREATED IRIS MELANOMA COMPLICATED BY HYPHEMA AND UNCONTROLLED GLAUCOMA RESPONSIVE TO IODINE-125 BRACHYTHERAPY.
Chang MY; McCannel CA; McCannel TA
Retin Cases Brief Rep; 2016; 10(1):44-7. PubMed ID: 26383516
[TBL] [Abstract][Full Text] [Related]
43. Posterior uveal melanoma in young patients treated with proton beam therapy.
Vavvas D; Kim I; Lane AM; Chaglassian A; Mukai S; Gragoudas E
Retina; 2010 Sep; 30(8):1267-71. PubMed ID: 20224468
[TBL] [Abstract][Full Text] [Related]
44. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
Marinkovic M; Horeweg N; Laman MS; Bleeker JC; Ketelaars M; Peters FP; Luyten GPM; Creutzberg CL
Br J Ophthalmol; 2018 Aug; 102(8):1154-1159. PubMed ID: 29122824
[TBL] [Abstract][Full Text] [Related]
45. Ocular complications after iodine brachytherapy for large uveal melanomas.
Puusaari I; Heikkonen J; Kivelä T
Ophthalmology; 2004 Sep; 111(9):1768-77. PubMed ID: 15350335
[TBL] [Abstract][Full Text] [Related]
46. Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma.
Verma V; Mehta MP
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e17-27. PubMed ID: 26915706
[TBL] [Abstract][Full Text] [Related]
47. Proton beam radiotherapy of iris melanoma.
Damato B; Kacperek A; Chopra M; Sheen MA; Campbell IR; Errington RD
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):109-15. PubMed ID: 16111578
[TBL] [Abstract][Full Text] [Related]
48. [Foreign bodies of the iris as a rare differential diagnosis of malignant melanoma of the iris].
Dunavoelgyi R; Dejaco-Ruhswurm I; Zehetmayer M
Klin Monbl Augenheilkd; 2007 May; 224(5):431-3. PubMed ID: 17516375
[TBL] [Abstract][Full Text] [Related]
49. Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma.
Akbaba S; Foerster R; Nicolay NH; Arians N; Bostel T; Debus J; Hauswald H
Radiat Oncol; 2018 Aug; 13(1):140. PubMed ID: 30071857
[TBL] [Abstract][Full Text] [Related]
50. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment.
Conway RM; Chua WC; Qureshi C; Billson FA
Br J Ophthalmol; 2001 Jul; 85(7):848-54. PubMed ID: 11423461
[TBL] [Abstract][Full Text] [Related]
51. Malignant melanomas of the iris.
Batioğlu F; Günalp I
Jpn J Ophthalmol; 1998; 42(4):281-5. PubMed ID: 9749868
[TBL] [Abstract][Full Text] [Related]
52. Secondary Glaucoma due to Iridescent Crystalline Particles Masquerading as Refractory Hypertensive Uveitis in an Eye With Irradiated Iris Melanoma.
Chahal R; Mohite AA; Heimann H; Bansal A
J Glaucoma; 2018 Apr; 27(4):385-388. PubMed ID: 29394206
[TBL] [Abstract][Full Text] [Related]
53. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.
Shields CL; Shah SU; Bianciotto CG; Emrich J; Komarnicky L; Shields JA
Ophthalmology; 2013 Jan; 120(1):55-61. PubMed ID: 22980742
[TBL] [Abstract][Full Text] [Related]
54. Whole anterior segment proton beam radiotherapy for diffuse iris melanoma.
Konstantinidis L; Roberts D; Errington RD; Kacperek A; Damato B
Br J Ophthalmol; 2013 Apr; 97(4):471-4. PubMed ID: 23298884
[TBL] [Abstract][Full Text] [Related]
55. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience.
Caujolle JP; Mammar H; Chamorey E; Pinon F; Herault J; Gastaud P
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):98-103. PubMed ID: 19910136
[TBL] [Abstract][Full Text] [Related]
56. Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma.
King B; Morales-Tirado VM; Wynn HG; Gao BT; Ballo MT; Wilson MW
Am J Ophthalmol; 2017 Apr; 176():40-45. PubMed ID: 28048976
[TBL] [Abstract][Full Text] [Related]
57. 20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
Bellocq D; Roy P; Kodjikian L; Mathis T; Nguyen AM; Herault J; Rivoire M; Négrier S; Thariat J; Grange JD
Melanoma Res; 2020 Jun; 30(3):272-278. PubMed ID: 30320630
[TBL] [Abstract][Full Text] [Related]
58. Visual Outcomes of Parapapillary Uveal Melanomas Following Proton Beam Therapy.
Thariat J; Grange JD; Mosci C; Rosier L; Maschi C; Lanza F; Nguyen AM; Jaspart F; Bacin F; Bonnin N; Gaucher D; Sauerwein W; Angellier G; Hérault J; Caujolle JP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):328-335. PubMed ID: 27084650
[TBL] [Abstract][Full Text] [Related]
59. Iris melanoma: risk factors for metastasis in 169 consecutive patients.
Shields CL; Shields JA; Materin M; Gershenbaum E; Singh AD; Smith A
Ophthalmology; 2001 Jan; 108(1):172-8. PubMed ID: 11150284
[TBL] [Abstract][Full Text] [Related]
60. Visual outcomes of macular melanocytic lesions after early or delayed proton beam therapy.
Nhari M; Thariat J; Kodjikian L; Chacun S; Nguyen AM; Rosier L; Herault J; Salleron J; Mathis T
Graefes Arch Clin Exp Ophthalmol; 2023 Jul; 261(7):2049-2059. PubMed ID: 36729331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
